DeepInfra | $107,000,000 | (May 5, 2026)
Kibu, Inc | $10,500,000 | (May 5, 2026)
Fun | $72,000,000 | (May 5, 2026)
Certified by Founder
Lodge
Latigo Biotherapeutics, Inc.
start up
United States
- Thousand Oaks, CA
- 15/02/2024
- Series A
- $135,000,000
Latigo Biotherapeutics Inc., headquartered in Thousand Oaks, CA, is a privately held clinical-stage biotechnology company developing best-in-class non-opioid pain medicines that target the fundamental mechanism of pain transduction. The company’s proprietary, in-house technology generates novel drugs against targets validated by human genetics using the most advanced artificial intelligence, machine learning, structure-based, and knowledge-based design techniques to optimize potency and selectivity. The company is backed by top-tier investors, including Westlake Village BioPartners, 5AM Ventures, Foresite Capital, and Corner Ventures.
- Industry Biotechnology Research
- Website https://latigobio.com/
- LinkedIn https://www.linkedin.com/company/latigobio/
Panthalassa | $140,000,000 | (May 5, 2026)
Featherless AI | $20,000,000 | (May 5, 2026)
Healthfab | $2,100,000 | (May 5, 2026)
LakeFusion | $7,500,000 | (May 5, 2026)
Enzo Health | $20,000,000 | (May 5, 2026)
Barocal | $10,000,000 | (May 5, 2026)
Zapdos Labs | $500,000 | (May 5, 2026)
Blomma | $5,000,000 | (May 1, 2026)
Dreambase | $3,700,000 | (May 1, 2026)